Trebananib, a peptide-Fc fusion protein, which binds both Ang-1 and Ang-2 preventing their interaction with Tie-2 receptor, has prolonged median progression free survival (PFS) by two months in phase 3 studies and showed antitumor activity with less class-specific adverse events in patients with recurrent ovarian cancer [9]. Here, ANGPT2 is linked to ovarian carcinoma.